<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ocugen Inc — News on 6ix</title>
<link>https://6ix.com/company/ocugen-inc</link>
<description>Latest news and press releases for Ocugen Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 11:02:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ocugen-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a59578dffbe2df10b2b9.webp</url>
<title>Ocugen Inc</title>
<link>https://6ix.com/company/ocugen-inc</link>
</image>
<item>
<title>Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-to-host-conference-call-on-tuesday-may-5-at-830-am-et-to-discuss-business-updates-and-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-to-host-conference-call-on-tuesday-may-5-at-830-am-et-to-discuss-business-updates-and-first-quarter-2026-financial-results</guid>
<pubDate>Wed, 29 Apr 2026 11:02:00 GMT</pubDate>
<description>MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 5, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call u</description>
</item>
<item>
<title>Ocugen to Present at April 2026 Investor and Industry Conferences</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-to-present-at-april-2026-investor-and-industry-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-to-present-at-april-2026-investor-and-industry-conferences</guid>
<pubDate>Thu, 23 Apr 2026 11:02:00 GMT</pubDate>
<description>MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer’s 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at O</description>
</item>
<item>
<title>Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-announces-early-completion-of-dosing-in-phase-23-pivotal-confirmatory-trial-of-ocu410st-for-stargardt-disease-1</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-announces-early-completion-of-dosing-in-phase-23-pivotal-confirmatory-trial-of-ocu410st-for-stargardt-disease-1</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST</description>
</item>
<item>
<title>Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-announces-topline-12-month-data-from-phase-2-armada-clinical-trial-evaluating-ocu410-modifier-gene-therapy-for-geographic-atrophy-secondary-to-dry-age-related-macular-degeneration</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-announces-topline-12-month-data-from-phase-2-armada-clinical-trial-evaluating-ocu410-modifier-gene-therapy-for-geographic-atrophy-secondary-to-dry-age-related-macular-degeneration</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment</description>
</item>
<item>
<title>Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-to-host-webcast-on-tuesday-march-24-at-8-am-edt-to-discuss-phase-2-clinical-trial-data-for-ocu410modifier-gene-therapy-for-geographic-atrophy</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-to-host-webcast-on-tuesday-march-24-at-8-am-edt-to-discuss-phase-2-clinical-trial-data-for-ocu410modifier-gene-therapy-for-geographic-atrophy</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies</description>
</item>
<item>
<title>Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-provides-business-update-with-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-provides-business-update-with-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 04 Mar 2026 13:15:00 GMT</pubDate>
<description>Conference Call and Webcast Today at 8:30 a.m. ETEnrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027.OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the seco</description>
</item>
<item>
<title>Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-announces-phase-3-limelight-enrollment-completion-for-ocu400-a-novel-modifier-gene-therapy-for-broad-retinitis-pigmentosa</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-announces-phase-3-limelight-enrollment-completion-for-ocu400-a-novel-modifier-gene-therapy-for-broad-retinitis-pigmentosa</guid>
<pubDate>Mon, 02 Mar 2026 12:02:00 GMT</pubDate>
<description>Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline Phase 3 data expected in 1Q 2027, advancing OCU400 towards potential approval in 2027 as a treatment option for early- to late-stage RPPositive long-term, 3-year Phase 1/2 durable, safety and tolerability data for OCU400 demonstrates sustained clinically meaningful, approximately 2-line LLV</description>
</item>
<item>
<title>Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-host-conference-call-wednesday-120200677</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-host-conference-call-wednesday-120200677</guid>
<pubDate>Wed, 18 Feb 2026 12:02:00 GMT</pubDate>
<description>MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to partici</description>
</item>
<item>
<title>Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-appoints-rita-johnson-greene-120200434</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-appoints-rita-johnson-greene-120200434</guid>
<pubDate>Mon, 09 Feb 2026 12:02:00 GMT</pubDate>
<description>MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). “Mrs. Johnson-Greene’s diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen’s CFO,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-f</description>
</item>
<item>
<title>Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-inc-announces-closing-225-million-underwritten-registered-direct-offering</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-inc-announces-closing-225-million-underwritten-registered-direct-offering</guid>
<pubDate>Fri, 23 Jan 2026 05:00:00 GMT</pubDate>
<description>MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today</description>
</item>
<item>
<title>Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-inc-announces-pricing-22-133200510</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-inc-announces-pricing-22-133200510</guid>
<pubDate>Wed, 21 Jan 2026 13:32:00 GMT</pubDate>
<description>MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for gross proceeds of $22.5 million, before deducting commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about January 22, 2026, subjec</description>
</item>
<item>
<title>Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-announces-positive-preliminary-phase-131500534</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-announces-positive-preliminary-phase-131500534</guid>
<pubDate>Thu, 15 Jan 2026 13:15:00 GMT</pubDate>
<description>Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical trials to date MALVERN, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positive preliminary 12-month data (~50% of patients evaluated to date) from the Phase 2</description>
</item>
<item>
<title>Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-host-webcast-thursday-january-15-8-30-am-et-discuss-ocu410-phase-2-clinical</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-host-webcast-thursday-january-15-8-30-am-et-discuss-ocu410-phase-2-clinical</guid>
<pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
<description>MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies</description>
</item>
<item>
<title>Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-announces-publication-phase-1-113000769</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-announces-publication-phase-1-113000769</guid>
<pubDate>Mon, 12 Jan 2026 11:30:00 GMT</pubDate>
<description>Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the publication of positive Phase 1 GARDian1 trial results for OCU410ST, its novel modifier gene therapy for Stargardt disease, in the peer-reviewed journal Na</description>
</item>
<item>
<title>Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-ceo-present-j-p-120200616</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-ceo-present-j-p-120200616</guid>
<pubDate>Fri, 09 Jan 2026 12:02:00 GMT</pubDate>
<description>MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026, at The Westin St. Francis in San Francisco, CA.“Year over year, Ocugen’s presence at the JPM Healthcare Conference has evolved and we are d</description>
</item>
<item>
<title>Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-ceo-present-oppenheimer-movers-rare-disease-summit-2025-12-10</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-ceo-present-oppenheimer-movers-rare-disease-summit-2025-12-10</guid>
<pubDate>Wed, 10 Dec 2025 05:00:00 GMT</pubDate>
<description>MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for</description>
</item>
<item>
<title>Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-ceo-present-noblecon21-noble-capital-markets-twenty-first-annual-emerging</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-ceo-present-noblecon21-noble-capital-markets-twenty-first-annual-emerging</guid>
<pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
<description>MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for</description>
</item>
<item>
<title>Ocugen Provides Business Update with Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-provides-business-update-third-quarter-2025-financial-results-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-provides-business-update-third-quarter-2025-financial-results-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Conference Call and Webcast Today at 8:30 a.m. ET Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License</description>
</item>
<item>
<title>Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-host-webcast-wednesday-november-5-8-30-am-et-discuss-business-updates-and</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-host-webcast-wednesday-november-5-8-30-am-et-discuss-business-updates-and</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies</description>
</item>
<item>
<title>Ocugen to Present at Industry and Investor Conferences in October 2025</title>
<link>https://6ix.com/company/ocugen-inc/news/ocugen-present-industry-and-investor-conferences-october-2025-2025-10-02</link>
<guid isPermaLink="true">https://6ix.com/company/ocugen-inc/news/ocugen-present-industry-and-investor-conferences-october-2025-2025-10-02</guid>
<pubDate>Thu, 02 Oct 2025 04:00:00 GMT</pubDate>
<description>MALVERN, Pa., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies</description>
</item>
</channel>
</rss>